SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending as community members discuss Elon Musk's recent purchase of $1 billion in TSLA shares, which many see as a strong signal of confidence. The move has sparked discussions about a potential short squeeze and the stock's future trajectory, with some anticipating a continued rally while others remain skeptical of the company's fundamentals.

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Atyr Pharma Inc

aTyr Pharma, Inc

Shares of ATYR are trending down following the release of Phase 3 study results, with the community discussing whether the stock is now undervalued given its cash position and potential for a rebound. Some traders are weighing the possibility of a dead cat bounce or long-term recovery, while others express concerns about the company's future prospects. The stock's significant drop has sparked debates about risk management and the influence of social media on investment decisions.

Helius Medical Technologies, Inc. is a neurotech company in the medical device industry that focuses on neurological wellness. The firm develops, licenses and acquires non-invasive platform technologies that amplify the brain’s ability to heal itself and reduce symptoms of neurological disease or trauma. It engages in the development of the investigational portable neuromodulation stimulator, that delivers neurostimulation via the tongue which has been shown in clinical studies to enhance the effectiveness of physical exercises in people with neurological symptoms from disease or trauma such as mild-to-moderate traumatic brain injury. The company was founded on March 13, 2014 and is headquartered in Newtown, PA.

Helius Medical Technologies Inc - Ordinary Shares - Class A

Helius Medical Technologies Inc

HSDT is trending due to speculation surrounding a potential SOL treasury announcement and recent positive outcomes from their stroke study, leading to discussions about a possible short squeeze. Community members are actively debating the stock's potential for a significant run, drawing comparisons to other companies that have launched crypto treasury initiatives. However, concerns remain regarding the company's history of reverse splits and dilution.

Asset Entities, Inc. engages in providing social media marketing and content delivery services. It offers its services to Discord, TikTok, and other social media platforms. It also designs, develops and manages servers for communities on Discord. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani and Kyle Fairbanks on August 1, 2020 and is headquartered in Dallas, TX.

Strive Inc. - Ordinary Shares - Class A

Asset Entities Inc.

Asset Entities Inc. ($ASST) is trending due to high volatility following its merger, with discussions focused on trading halts and the potential for a short squeeze. The community is debating the impact of a new share repurchase program and potential Bitcoin purchases, while also noting the CUSIP change affecting trading on some platforms. Overall, traders are closely watching the stock's price action and the potential for significant swings.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble is trending as investors discuss a potential TikTok deal and JD Vance's show on the platform, while also focusing on the high short interest. Community talking points include speculation about a short squeeze, the upcoming Rumble wallet, and the impact of Tether's involvement. Broader discussions revolve around the company's cloud business and potential acquisition of Northern Data.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation is trending as the community discusses potential catalysts like FAA certification and new partnerships, while also debating whether recent price action indicates a buying opportunity or further downside. Some speculate about government contracts and compare ACHR to competitors like $JOBY in the eVTOL space. Concerns about a short report and the CEO's communication are also prevalent.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is trending due to a mix of bullish news, including a new $6.3B cloud capacity deal with Nvidia, and bearish sentiment from Kerrisdale Capital announcing a short position with a 90% downside target. The community is debating the impact of the Nvidia deal, potential UK data center investments, and whether the recent price action is setting up for a short squeeze or a further pullback. Discussions also revolve around insider selling and its effect on investor confidence.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IONQ is trending due to renewed investor optimism surrounding quantum computing, fueled by recent regulatory approval for its acquisition of Oxford Ionics and the launch of IonQ Federal. Community discussions revolve around the company's growth potential, upcoming Analyst Day, and comparisons to other quantum computing firms. Some traders are pointing towards technical breakouts, while others are wary of the high valuation.

NanoVibronix, Inc. engages in the development of noninvasive biological response-activating devices. The firm's products include UroShield and PainShield. It operates through the following geographical segments: United States, Europe, Australia, India, Israel, and Other. The company was founded by Harold Jacob and Jona Zumeris in September 2003 and is headquartered in Tyler, TX.

NanoVibronix Inc

NAOV is trending due to a recent patent announcement regarding its ENvue Medical division's technology, sparking significant community interest. Discussions revolve around the stock's low float and potential for a short squeeze, although some traders express caution due to the company's history of reverse stock splits. The stock is seeing increased volume as traders weigh the impact of the patent and speculate on future price movement.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

Applied Digital ($APLD) is trending as investors celebrate news that a tenant, CoreWeave, signed a large order form with NVIDIA, signaling strong demand for data center capacity and AI infrastructure. The community is optimistic about APLD's prospects in the AI sector and anticipates further announcements regarding new partnerships and data center developments. Bullish sentiment is fueled by the potential for a short squeeze and the company's strategic positioning in the growing AI market.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Cidada Therapeutics doubled in value on Monday&nbsp;and jumped in after-hours trading as the biotech firm released positive results from a trial of its flu drug candidate,&nbsp;managing to offset pressure from plans for a $250 million share offering.Cidara will offer all shares, and underwriters will receive a 30-day option to buy up to 15% more shares.&nbsp;J.P. Morgan, Morgan Stanley, Guggenheim Securities, and Cantor are leading the deal.&nbsp;The disclosure&nbsp;follows a&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/cidara-therapeutics-market-cap-doubles-after-investigational-drug-shows-positive-results-in-preventing-influenza/chm5alCRRdd">mid-stage trial of CD388</a>, a long-acting antiviral being developed to protect against seasonal flu.&nbsp;In the trial, which enrolled healthy adults between 18 and 64 who had not been given flu vaccines, CD388 was administered in three single doses.Each dose showed statistically meaningful protection against the flu over a 24-week period, with the highest dose offering up to 76% protection.Cidara said the treatment was well tolerated at all tested levels, with no significant safety concerns.Based on the outcome, the company has formally asked the U.S. Food and Drug Administration (USFDA) to hold a meeting to review the findings and discuss next steps for a Phase 3 trial.CD388 is being developed using Cidara’s Cloudbreak platform and is designed to offer once-per-season protection against both influenza A and B viruses.&nbsp;The company expects to share further results at upcoming medical meetings.Following the update, H.C. Wainwright raised its price target on Cidara Therapeutics to $53 from $41, citing strong mid-stage trial results for CD388 and boosting its success probability to 75%.&nbsp;RBC Capital also lifted its target to $75 from $35, calling CD388 a potentially groundbreaking long-acting flu preventative.On Stocktwits, retail sentiment was ‘extremely bullish’ amid a 31,400% surge in 24-hour message volume.One user said Cidara’s rally was unusual for a company announcing a large capital raise, warning short sellers to be cautious.&nbsp;<stembedurl>https://stocktwits.com/Stmkr/message/618765398</stembedurl>Another user noted that no price had been set for the offering yet and said they planned to watch how the situation unfolds in the next session.<stembedurl>https://stocktwits.com/Lstreak/message/618734296</stembedurl>The stock has risen 64.7% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Cidara Therapeutics Stock Jumps After-Hours As Strong Flu Trial Data Outweighs $250M Share Offering

The offering is being led by J.P. Morgan, Morgan Stanley, Guggenheim Securities, and Cantor.

Equity

Cidara Therapeutics, Inc. (CDTX) on Monday <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.cidara.com/news/cidara-therapeutics-announces-positive-topline-results-from-its-phase-2b-navigate-trial-evaluating-cd388-a-non-vaccine-preventative-of-seasonal-influenza/">announced</a> positive results from its mid-stage trial evaluating CD388 for the prevention of seasonal influenza in healthy unvaccinated adults aged 18 to 64.Cidara’s shares nearly doubled in value as of Monday afternoon.Single doses of 450mg, 300mg, and 150mg of CD388 conferred 76%, 61%, and 58% protection, respectively, from symptomatic influenza over 24 weeks compared to placebo, the company said. The doses were administered at the beginning of the flu season.CD388 was well-tolerated at all doses with no unexpected dose-limiting treatment-emergent adverse events observed, the company added.CD388 is not a vaccine. Instead, it is an investigational drug-Fc conjugate (DFC), or low molecular weight biologics, which are designed to function as long-acting small molecule inhibitors.As it is not a vaccine, its activity is not reliant on an immune response and, thereby, is expected to be efficacious in individuals regardless of immune status.CEO Jeffrey Stein stated that the trial results reinforce the company’s confidence in the potential of CD388 to provide seasonal protection against influenza A and B.Cidara stated that it has submitted a request to the U.S. Food and Drug Administration to review the results of the mid-stage trial and discuss the design and timing of a late-stage trial.Following the update, H.C. Wainwright raised its price target on Cidara to $53 from $41 and kept a ‘Buy’ rating on the shares.The new price target implies a 152% upside to the stock’s closing price on Friday.The analyst further increased the probability of success for CD388 to 75% from 60% based on the positive mid-stage trial data.RBC Capital also raised the firm's price target on Cidara Therapeutics to $75 from $35 while keeping an 'Outperform' rating on the shares. The results from the recent study position CD388 as a potential groundbreaking, long-acting flu preventative that could combine and enhance the benefits of existing vaccines and prophylactics, it said.On Stocktwits, retail sentiment around Cidara soared from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours while message volume increased from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:627/67;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_23_at_1_07_39_PM_png_569e678349.webp" alt="CDTX's Sentiment Meter and Message Volume as of 1:05 p.m. ET on June 23, 2025 | Source: Stocktwits" width="627" height="67"><figcaption>CDTX's Sentiment Meter and Message Volume as of 1:05 p.m. ET on June 23, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user highlighted the company’s debt-free status and strong cash position.<stembedurl>https://stocktwits.com/Vulcooo/message/618688709</stembedurl>Cidara ended the first quarter with $174.5 million in cash, cash equivalents, and restricted cash.<a href="https://stocktwits.com/symbol/CDTX">CDTX stock</a> is up by about 56% this year and by about 272% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/compass-pathways-stock-slumps-after-positive-late-stage-trial-results-from-psychedelic-drug-underwhelm-analysts/chm59LwRRdc">Compass Pathways Stock Slumps After Positive Late-Stage Trial Results From Psychedelic Drug ‘Underwhelm’ Analysts</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Cidara Therapeutics’ Market Cap Doubles After Investigational Drug Shows Positive Results In Preventing Influenza In Mid-stage Trial

Single doses of 450mg, 300mg, and 150mg of CD388 conferred 76%, 61%, and 58% protection, respectively, from symptomatic influenza over 24 weeks compared to placebo, the company said.

Cidara Therapeutics: A Strong Buy on Promising Trials and Strategic Milestones

Cidara Therapeutics (CDTX Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Stringer...

CDTX INVESTOR NOTICE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - CDTX

CDTX INVESTOR NOTICE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - CDTX CDTX INVESTOR NOTICE: ROSEN, TOP...

CDTX LOSS ALERT: ROSEN, A LEADING LAW FIRM, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation CDTX

WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Cidara Therapeutics, Inc. (NASDAQ: CDTX) resulting from...

Cidara Therapeutics Presents Promising New Data on Novel Drug-Fc Conjugate Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2024

- Multispecific CD73/PD-1 DFC demonstrates improved tumor reduction compared to PD-1 monotherapy in nonclinical study - CCR5-targeting DFC demonstrates potent efficacy in colorectal cancer...

Insider Selling: Cidara Therapeutics, Inc. (NASDAQ:CDTX) Insider Sells 21,029 Shares of Stock

Cidara Therapeutics, Inc. (NASDAQ:CDTX  Get Free Report) insider Leslie Tari sold 21,029 shares of the businesss stock in a transaction that occurred on Monday, March 11th. The shares...

Insider Selling: Cidara Therapeutics, Inc. (NASDAQ:CDTX) CFO Sells 18,931 Shares of Stock

Cidara Therapeutics, Inc. (NASDAQ:CDTX  Get Free Report) CFO Preetam Shah sold 18,931 shares of the businesss stock in a transaction that occurred on Monday, March 11th. The stock was...

Cidara Therapeutics to Present Preclincal Data on Multiple Novel Drug-Fc Conjugate Candidates at American Association dor Cancer Research (AACR) Annual Meeting 2024

Abstracts to include preclinical data on several drug-Fc conjugate (DFC) candidates including multispecific CD73/PD-1 DFC, CCR5 targeting DFC and CBO421 (CD73 targeting DFC)SAN DIEGO, March 06, 2024...

Cidara Therapeutics Receives $11.14 Million Milestone Payment Following European Approval of REZZAYO

Approval triggered by positive results from ReSTORE Phase III clinical trialPayment will advance Cidara's Cloudbreak platform for the development of drug-Fc conjugates (DFCs) SAN DIEGO, Feb...

Cidara Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, and commercialization of therapeutics for patients facing serious diseases, specifically oncology and infectious diseases. Its product pipeline includes Rezafungin Acetate and Cloudbreak. The company was founded by Kevin M. Forrest, Kevin J. Judice, and H. Shaw Warren in December 2012 and is headquartered in San Diego, CA.

CDTX
Cidara Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CDTX News

CDTX Cidara Therapeutics Inc